(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(amc 2024-05-08)
Expected move: +/- 11.84%
Live Chart Being Loaded With Signals
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain...
Stats | |
---|---|
今日成交量 | 240 995 |
平均成交量 | 138 824 |
市值 | 14.58M |
EPS | $0 ( 2024-04-04 ) |
下一个收益日期 | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.313 |
ATR14 | $0.0740 (8.03%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-15 | Nantahala Capital Management, Llc | Buy | 0 | Common Stock |
2023-07-20 | Nantahala Capital Management, Llc | Buy | 2 205 883 | 2023 Series A Warrants |
2023-07-20 | Nantahala Capital Management, Llc | Buy | 2 205 883 | 2023 Series B Warrants |
2023-07-20 | Nantahala Capital Management, Llc | Buy | 750 883 | 2023 Pre-Funded Warrants |
2024-03-15 | Nantahala Capital Management, Llc | Buy | 755 000 | Call Option (Right to Buy) |
INSIDER POWER |
---|
82.74 |
Last 92 transactions |
Buy: 3 436 001 | Sell: 171 828 |
音量 相关性
AcelRx Pharmaceuticals 相关性 - 货币/商品
AcelRx Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $651 000 |
毛利润: | $651 000 (100.00 %) |
EPS: | $-0.000700 |
FY | 2023 |
营收: | $651 000 |
毛利润: | $651 000 (100.00 %) |
EPS: | $-0.000700 |
FY | 2022 |
营收: | $1.77M |
毛利润: | $-820 000 (-46.30 %) |
EPS: | $5.73 |
FY | 2021 |
营收: | $2.82M |
毛利润: | $-935 000 (-33.18 %) |
EPS: | $-5.86 |
Financial Reports:
No articles found.
AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。